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Abstract
Aims: We evaluated a Selective Bladder Denervation (SBD) device, which uses radiofrequency
ablation, for the treatment of overactive bladder syndrome in terms of its nerve denervation,
ablation characteristics, and post-treatment healing.
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Methods: Using the SBD device, eight fresh extirpated ovine bladder trigones were treated (90°C
set point for 60 s) and nitroblue tetrazolium viability stained to characterize the ablation. In
addition, 12 trigones were treated in vivo with three adjacent ablations and divided into survival
cohorts: Day 7, Day 30, and Day 90 to assess the ablations and their associated healing.
Results: The ex vivo single trigone ablations had a 7.9 ± 0.9 mm width and 5.7 ± 1.0 mm
thickness that involved the submucosa, detrusor muscle, adventitia, and vagina. Microscopic
viability staining confirmed complete nerve necrosis within the targeted tissue. The in vivo Day 7
trigones supported the ex vivo ablation characteristics and showed up to minimal inflammation,
granulation tissue, and collagen fibrosis. Day 30 trigones had essentially absent inflammation and
granulation tissue with evolving collagen fibrosis at the ablation's periphery. Day 90 trigones had
essentially absent acute inflammation, minimal chronic inflammation, essentially absent
granulation tissue, and up to mild collagen fibrosis. No ureteral/urethral alterations, vesico-vaginal
fistulas, or other complications were identified.
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Conclusions: The SBD device provided a targeted trigone ablation with resultant denervation.
The tissue healing timeline followed that expected for a hyperthermic ablation and was

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial
purposes.http://creativecommons.org/licenses/by-nc/4.0/
Correspondence James E. Coad, MD, Pathology Laboratory for Translational Medicine, West Virginia University Department of
Pathology, HSC-North, Mailstop 9203, 1 Medical Center Drive, 26506 Morgantown, WV., jcoad@hsc.wvu.edu.
Performing Laboratories: (1) Pathology Laboratory for Translational Medicine, West Virginia University School of Medicine,
Morgantown, WV 26506.
(2) American Preclinical Services, LLC 8945 Evergreen Blvd., Minneapolis, MN 55433.

Fugett et al.

Page 2

Author Manuscript

characterized by a fibroproliferative healing response with limited inflammation and granulation
tissue. The ablations did not impact the overlying bladder mucosal surface.
Keywords
denervation; overactive bladder; tissue ablation; tissue healing

1∣

INTRODUCTION
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Overactive Bladder (OAB) is a condition that affects approximately 17% of women in the
United States.1 It is characterized by urinary urgency that may have associated urge
incontinence, increased frequency, and/or nocturia.2 Physiologically, micturition is achieved
by parasympathetic stimulation of the detrusor muscle with simultaneous relaxation of the
bladder outlet.3 More specifically, the pelvic nerves stimulate muscarinic acetylcholine
receptors within the bladder's trigone that initiate detrusor muscle contraction and
subsequent urination.
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While the pathophysiologic mechanism(s) of OAB have not been definitively ascertained,
investigators have proposed both neurogenic and myogenic etiologies. The neurogenic
etiology postulates that afferent innervation of the urothelial mucosa and submucosa
provides altered luminal sensing that leads to urgency and unstable detrusor contractions.4,5
Afferent nerves in the bladder are predominantly made of two fiber types: Aδ and C-fibers.
Aδ fibers are thought to transmit stretch signals from throughout the bladder while C-fibers
predominantly transmit signals related to bladder irritation and are located predominantly
within the base of the bladder.6 It is not known what role, if any, C-fibers play in normal
micturition; but, they are up-regulated in hypersensitive bladder conditions such as cystitis,
neurogenic bladder, and OAB. Teleological arguments have been proposed that suggest the
role of C-fibers is to detect noxious/chemical stimuli or infections in the bladder. There is
increasing evidence that the symptoms of OAB are caused by these afferent C-fiber type
nerves that are densely located below the trigone. Thus, the trigone has been the focus of
several studies on C-fiber activation and bladder hypersensitivity.7
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Stemming from this proposed mechanism, a number of therapeutic approaches to alleviate
OAB symptoms have emerged, including systemic pharmacological muscarinic receptor
inhibition, adrenergic stimulation, intravesical OnabotulinumtoxinA injections, and the
Modified Ingelman-Sundberg (MIS) surgical denervation procedure. As muscarinic
receptors are expressed in several different tissues (including salivary glands and intestines),
systemic muscarinic antagonists do not exclusively target the bladder with resultant possible
clinical side effects unrelated to the patient's OAB.8,9 Similarly, adrenergic receptors are also
located throughout the body with resultant side effects, especially important being
cardiovascular effects.10 While more targeted than the systemic approach with potentially
fewer side effects, OnabotulinumtoxinA injections provide a minimally invasive treatment
that needs to be repeated to maintain clinical efficacy.11 While potentially more durable, the
MIS procedure involves an invasive surgery with more tissue disruption, longer recovery
time, and potential for inter-procedural variations.12,13 Therefore, an OAB therapy that
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combines a minimally invasive targeted approach with clinical durability would improve
therapeutic options for these patients.
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A minimally invasive Selective Bladder Denervation (SBD) device (Amphora Medical,
Maple Grove, MN) has been designed for the treatment of OAB (Figure 1A). The system
includes a disposable transurethral device that accepts a rigid endoscope for visualization
and has a lumen to facilitate addition and removal of fluids in the bladder. At the end of the
lumen is a suction paddle to allow stabilization of the tissue and facilitate delivery of the RF
electrodes powered by a suitable RF generator. The SBD device has been designed to
provide a bipolar RF trigone-targeted ablation that denervates the underlying nerves that is
followed by a type 1 collagen fibroproliferative healing response. As the clinical outcome is
dependent on both the tissue's primary thermal ablation and healing response, the purpose of
this study was to determine the SBD device's ablation characteristics and assess its resultant
healing response using the Day 0 (extirpated) and in vivo Day 7, Day 30, and Day 90 ovine
bladder model.

2 ∣ MATERIALS AND METHODS
2.1 ∣

Ex vivo bladder preparation, treatment, and evaluation
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Fresh non-frozen extirpated ovine bladders, with preservation of the surrounding tissues
including the vagina, were received from a local abattoir within 2 h of the ovine's euthanasia.
The bladders were ventrally opened via a midline sagittal incision from the bladder neck to
dome (Figure 1B). The bladders were pinned for stabilization, secured in a thin walled
plastic bag with a saline gauze for humidification, and brought to 37 ± 1°C in a saline bath
just prior to ablation. After removing the plastic bag, the SBD device was positioned over
the trigone in the saline bath, stabilized using the mucosal suction paddle, and then two RF
electrodes were inserted into the underlying bladder wall. The bladders were treated with the
SBD device powered by a RF generator (Neurotherm NT 2000iX, Abbott Laboratories,
Abbott Park, IL), using Lesion Mode to maintain a 90°C temperature set point for 60 s based
on prior developmental studies performed to identify the treatment parameters needed to
create the optimal ablation described in this study.
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The post-ablated bladders were maintained for approximately 3 h at room temperature after
the ablation, rapidly frozen to −80°C, transversely sectioned based on the suction paddle
location, embedded on OCT cryomolds, frozen sectioned at 10 microns, nitro blue
tetrazolium (NBT)-stained (Figure 1C) and evaluated using routine light microscopy. Tissue
controls were also prepared, NBT-stained, and evaluated from the adjacent non-treated
trigone region to ensure preservation of tissue quality and viability during the procedure.
The NBT cytochemical viability stain utilizes intracellular dehydrogenase enzyme
(diaphorases) with its cofactor (NADH/NADPH) to convert the colorless tetrazolium salt
into a blue/violet formazan pigment in tissues with preserved enzymatic activity (NBTpositive, viable tissue). Ablated tissues, in which this enzymatic pathway is unable to
metabolize the tetrazolium, do not stain and remain their native color (yellow-tan, NBTnegative, non-viable tissue).
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In vivo bladder treatment, necropsy, tissue preparation, and evaluation
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The in vivo testing was performed at American Preclinical Services (APS, Minneapolis,
MN) a licensed test facility with the United States Department of Agriculture to conduct
research in laboratory animals. This study was reviewed and approved by the APS
Institutional Animal Care and Use Committee (IACUC) prior to study initiation and was
performed in accordance with Good Laboratory Practices (GLP). Each animal was prepped,
brought to the procedure room, catheterize to drain the bladder, and then the bladder was
filled with sterile saline until the urothelial bladder wall folds were visually removed. The in
vivo treatments consisted of three adjacent ablations with the same parameters as the ex vivo
ablations (Lesion Mode to maintain a 90°C temperature set point for 60 s). After visually
localizing the suction paddle within the trigone and inserting the two electrodes into the
bladder wall, radiofrequency energy was used to ablate the targeted bladder wall and
associated nerves. The animals were then survived for 7 ± 1, 30 ± 2, or 90 ± 2 days prior to
euthanasia.
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Following euthanasia, an abdominal and pelvic necropsy was performed. Upon opening the
abdominal cavity, the bowel, urinary bladder, ureters, kidneys, uterus, cervix, vagina,
rectum, urethra, and other abdominal/pelvic structures were inspected in situ for any
macroscopic signs of thermal injury and/or lesions. The distal ureters, urinary bladder,
urethra, uterus, fallopian tubes, ovaries, cervix, vagina, rectum, and surrounding tissues were
then dissected en bloc and fixed in 10% neutral buffered formalin. The urinary bladder,
including the trigone and ureteral ostia, was transversely sectioned (approximately 5-8 mm
intervals) from the proximal urethra across the bladder neck to the bladder apex. The trigone
region, to encompass both the ablation and ureteral ostia, was submitted for routine formalin
fixation, paraffin embedding, and both hematoxylin and eosin and trichrome staining on 5micron tissue sections.
2.3 ∣

Microscopic evaluation
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The slides were histologically evaluated to characterize the ablations, including the involved
tissue layers (epithelium, submucosa, detrusor muscle, adventitia, and/or deeper tissue
extension). The residual ablation size was measured using a calibrated ocular micrometer to
within ± 0.1 mm. In addition, the ablation-associated tissue healing reactions were scored
for acute inflammation, chronic inflammation, granulation tissue, fibrosis, and overall
healing stage (Table 1). In brief, polymorphonuclear leukocyte inflammation was defined as
the presence of PMN-neutrophils at or associated with the ablation site. Chronic
inflammation was defined as the presence of lymphocytes, histiocytes (monocyte-derived
cells) and/or plasma cells associated with the ablation site. Granulation tissue was defined as
the presence of new capillary angiogenesis in a loose connective tissue background
associated with the ablation site. Fibrosis was defined as the presence of fibrocollagenous
tissue healing, as a result of a wound-type healing reaction at the ablation site. The overall
stage of healing was scored as essentially absent, loose early (granulation tissue with
inflammation), primary healing (collagen deposition), or secondary healed scar.
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RESULTS

3.1 ∣ Ex vivo bladder treatments
The eight ex vivo trigone single ablations had a mean NBT-negative width of 7.9 ± 0.9 mm
and thickness of 5.7 ± 1.0 mm. These ablations were performed without difficulty. The NBTstained sections demonstrated that each of the ablations (n = 8) involved the underlying
submucosa, detrusor muscle, adventitia, and adjacent vaginal wall tissues (Figures 1C and
2A). The adjacent non-treated trigone tissue from the bladders histologically confirmed the
preservation of intact viable tissue without any alterations in NBT staining, thermal tissue
changes, or tissue degradation.
3.2 ∣ In vivo bladder treatments (n = 4) – day 7 microscopic evaluation (Figure 2B)
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No procedural or post-procedural treatment-related complications were identified during the
in life post-treatment follow-up period and necropsies. All of the Day 7 trigone ablations
involved the submucosa, detrusor muscle, adventitia, and vagina (100%). The three adjacent
ablations approximated 16.3 ± 1.2 mm (median: 16.3 mm) in width and 8.4 ± 1.6 mm
(median: 8.5 mm) in height (Table 2). The ablations were all histologically characterized by
thermal tissue necrosis (coagulative necrosis with pale ghost-like tissue staining) with
essentially absent (25%), minimal (50%) to mild (25%) acute inflammation (scaled score:
0.8 ± 0.8, median 0.5), essentially absent (50%) to minimal (50%) chronic inflammation
(scaled score: 0.5 ± 0.5, median 0.5), patchy minimal (75%) to mild (25%) granulation
tissue (scaled score: 1.3 ± 0.4, median 1.0), and essentially absent collagen fibrosis (scaled
score: 0.0 ± 0.00, median 0) at the ablation's edge, consistent with the early phase of tissue
healing.
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3.3 ∣ In vivo bladder treatments (n = 4) – day 30 microscopic evaluation (Figure 2C)
No procedural or post-procedural treatment-related complications were identified during the
in life post-treatment follow-up period and necropsies. The Day 30 trigone ablations
involved the urothelium (25%), submucosa (25%), detrusor muscle (100%), adventitia
(100%), and/or outer vaginal wall (75%). The healing ablation sites approximated 13.9 ± 2.8
mm (median: 14.0 mm) in width and 2.6 ± 0.9 mm (median: 2.3 mm) in height (Table 2).
The ablations were characterized by essentially absent (75%) to moderate (25%) acute
inflammation (scaled score: 0.8 ± 1.3, median 0), minimal (50%) to moderate (50%) chronic
inflammation (scaled score: 2.0 ± 1.0, median 2.0), essentially absent (75%) to mild (25%)
granulation tissue (scaled score: 1.0 ± 0.7, median 1.0), and a minimal (25%) to mild (75%)
increase in collagen fibrosis (scaled score: 1.8 ± 0.4, median 2.0), consistent with primary
phase of tissue healing.
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3.4 ∣ In vivo bladder treatments (n = 4) – day 90 microscopic evaluation (Figure 2D)
No procedural or post-procedural treatment-related complications were identified during the
in life post-treatment follow-up period and necropsies. The Day 90 ablated trigone regions
involved the detrusor muscle (100%), adjacent adventitia (100%), and approximated 13.1
± 4.5 mm (median: 13.1 mm) in width and 1.3 ± 0.3 mm (median: 1.3 mm) in height (Table
2). The ablation sites were characterized by essentially absent acute inflammation (100%,
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scaled score: 0.0 ± 0.00, median 0), minimal (25%), mild (50%) to extensive (25%) chronic
inflammation (scaled score: 2.3 ± 1.1, median 2.0), essentially absent granulation tissue
(100%, scaled score: 0.0 ± 0.00, median 0), and a moderate increase in collagen fibrosis
(scaled score: 3.0 ± 0.00, median 3.0), consistent with the secondary phase of tissue healing.

4 ∣ DISCUSSION
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Normal micturition is the result of voluntarily initiated parasympathetic stimulation of the
detrusor muscle resulting in contraction of the detrusor. It is thought that up-regulation of
sensory afferent nerves, in the bladder's trigone and base, result in the sensation of urgency
at small bladder volumes.14,15 This then causes an involuntary contraction of the detrusor
via a spinal reflex and leads to urgency incontinence. Past investigators have proposed the
modified Ingelman-Sundberg (MIS) procedure as a treatment for OAB. This surgical
procedure involves an anterior vaginal wall incision followed by a sharp dissection to
separate the vaginal wall from the bladder. This effectively resulted in denervation of the
afferent supply to the bladder base and trigone. A patient’s potential response to sub-trigonal
denervation can be pre-operatively assessed using local anesthetics, such as bupivacaine,
injected into this region.13 Patients who demonstrated a reduction in symptoms and
subsequently underwent a MIS procedure showed a partial to complete long-term response
following surgery in 68% of cases.13 More recently, OAB has been treated with less invasive
approaches, including OnabotulinumtoxinA injection, with shorter periods of symptomatic
relief necessitating retreatment. Therefore, an OAB therapy that combines a minimally
invasive targeted approach with clinical durability would improve therapeutic options for
these patients.
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The SBD device (Amphora Medical) provides targeted bipolar radiofrequency trigone
ablation to thermally denervate the underlying sensory nerves, which is then followed by a
type 1 collagen fibroproliferative healing response. The SBD device emulates the MIS
procedure in that they both denervate the trigone with a subsequent type 1 fibroproliferative
healing response that may serve as a potential barrier to re-innervation; however, the SBD
device does such in a significantly less invasive fashion.
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The MIS procedure is technically challenging and inadvertent entry into the bladder lumen
can occur. In contrast, the SBD device is minimally invasive. It utilizes cystoscopic guidance
through the urethra to the trigone where two bipolar radiofrequency electrodes are inserted
to ablate the nerves that course through the region between the bladder and vaginal walls.
Various routes to access this targeted ablation region were considered. The transurethral
route was selected given its minimally invasive nature and the ability to directly visualize
treatment landmarks (ureteral ostia and bladder neck), more standardized distance between
the urothelium and underlying target tissue than perineal or vaginal approaches and a more
sterile approach that the clean-contaminated nature of a vagina operative field, In addition to
radiofrequency energy, other thermotherapy modalities may have the potential to similarly
achieve similar trigonal denervation.
Given its similarities with the human urinary bladder wall thickness, the ovine bladder
model was utilized to assess the SBD Device's resultant tissue effects. Although human
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bladders are similar in volume to canine and swine, these models have thinner bladder walls.
As this study was focused on the bladder wall's treatment effects, it was preferable to use the
ovine model with a more similar wall thickness rather than overall size and shape.16 As this
treatment will initially be studied in women, the female ovine model was chosen to evaluate
this device in the most representative anatomy, which included the vaginal wall and
overlying bladder trigone.
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With regards to correlations with the human bladder, ultrasonography of the trigone region's
bladder wall thickness was 5.8 ± 0.1 mm based on the study of 492 female patients.17 In a
separate study, patients with OAB were shown to have a greater bladder wall thickness
compared to non-OAB patients (4.3 ± 1.21 mm and 3.3 ± 1.01 mm, respectively).18 Based
on the evaluation of 14 female cadavers, Amphora Medical (unreported data) found the
adventitial thickness, between the bladder wall and vagina, to be approximately 1 mm. The
underlying anterior vaginal wall thickness has been reported to be 2.7 ± 0.6 mm.19
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Using the ex vivo fresh ovine bladder model, the SBD device demonstrated its ability to
target the underlying trigonal nerves within the submucosa, detrusor muscle, and adventitia.
Within these ablations, NBT viability staining confirmed complete necrosis of the nerves
within and passing through the sub-trigone region, which would result in the interruption of
afferent and efferent nerve signaling below the urothelium (Figures 3A and 3B).
Subsequently, the in vivo ablations had similar tissue ablation characteristics (Figures 3C
and 3D). At Day 7, the ablations were characterized by thermal tissue necrosis with minimal
associated tissue healing. At 30 days there was variable residual thermal tissue necrosis,
minimal inflammation, and early collagen deposition that began to replace the local tissues,
consistent with the primary stage of healing. At Day 90, no residual thermal tissue necrosis
remained with complete replacement by mature type 1 collagen, consistent with the
secondary stage of healing. This fibrosis layer showed linearized compacted collagen fibrils
that formed a dense tissue mat that connected with the detrusor muscle on either side of the
ablation. This latter layer of collagen rich fibrosis histologically replaced the nerves and
tissues that originally comprised this region and should provide a barrier to resist reinnervation of and through the ablated region. Future studies with longer follow-up will be
necessary to fully assess the potential for trigonal re-innervation following the SBD
procedure. Overall, the healing timeline in this study is within that expected for a focused/
localized hyperthermic ablation.
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This minimally invasive device was designed to mitigate the risk of potential for side effects,
including unintended adjacent tissue injury (ureteral ostia, bladder neck, and adjacent
organs), urinary retention, and vesico-vaginal fistula formation. The direct visualization of
the ureteral ostia and bladder neck in combination with a suction paddle to stabilize the
tissue during the ablation protect these adjacent structures. While indiscriminate nerve
ablation within bladder could lead to bladder dysfunction, urinary retention, or worsening
OAB and inadvertent bladder neck ablation could lead to worsening stress urinary
incontinence (SUI), the Amphora OAB System specifically limits denervation to the subtrigone region, while leaving the remainder of the bladder body and neck untreated. The
intent of this is to denervate the C-fibers in the trigone thought to be responsible for OAB,
while preserving the remaining C-fibers, Aδ fibers, and efferent fibers of the bladder to
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sense the degree of luminal filling and provide normal contraction of the bladder wall. This
approach is supported by prior studies showing that chemo-denervation of the trigone region
alone have lower rates of acute urinary retention compared to chemo-denervation of the
bladder body while maintaining similar efficacy.20,21 Although further study will be
necessary to prove clinical safety, these findings suggest that the SBD device procedure will
result in a tolerable safety profile.

5∣

CONCLUSIONS
Our results suggest that the Selective Bladder Denervation device can provide a targeted
denervation of the trigone with an appropriate healing response. This may be a promising
option for treatment of patients with the Overactive Bladder Syndrome and further clinical
studies are warranted.
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FIGURE 1.
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A, Illustration of SBD device placement at the bladder trigone. B, Extirpated bladders were
ventrally opened from bladder neck to the apex. C, NBT-stained transverse trigone cross
sections (from shaded blue triangle correlating with sections 1, 2, and 3) showing the
underlying tan NBT-negative ablation (approximately 5× magnification and with 2 mm cross
bar scale)

Author Manuscript
Neurourol Urodyn. Author manuscript; available in PMC 2019 September 01.

Fugett et al.

Page 11

Author Manuscript
Author Manuscript

FIGURE 2.

Trigone ablation histology. A, Representative NBT staining of a fresh extirpated Day 0
trigone. B, Representative Day 7 trigone ablation (10× magnification, hematoxylin and
eosin-stained). C, Representative Day 30 trigone ablation (10× magnification, hematoxylin
and eosin-stained). D, Representative Day 90 trigone ablation (10× magnification,
hematoxylin and eosin-stained)
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FIGURE 3.

Selective bladder denervation following ablation with the SBD Device. Representative NBT
viability stained fresh extirpated bladder (Day 0, A and B) and Day 7 post-ablation
hematoxylin and eosinstained (C and D) trigone region nerves (100× magnification). A,
Viable NBT-positive (purple) nerves are illustrated from the adventitia outside of the
ablation (black arrows). B, Non-viable NBT-negative (tan) nerves are illustrated from within
the ablation (black arrows). C, Corresponding viable nerves, stained with hematoxylin and
eosin, are illustrated from the tissue surrounding the ablation (black arrows). D,
Corresponding non-viable necrotic nerves, stained with hematoxylin and eosin, are
illustrated from within the ablation (black arrows)
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Absence of PMNs

Rare individual PMNs

Scattered PMNs without
clustering

PMNs with focal clustering

PMNs with more confluent
infiltration

0 (None)

1 (Minimal)

2 (Mild)

3 (Moderate)

4 (Extensive)

Score

Acute inflammation

More confluent chronic inflammatory cell
infiltrate

Multifocal chronic inflammatory cell
clusters

Frequent scattered or focally clustered
chronic inflammatory cells

Occasional scattered chronic inflammatory
cells

Absence of chronic inflammatory cells

Chronic inflammation

Granulation tissue involving more than 50% of
the area surrounding ablation

Granulation tissue involving 26-50% of the area
surrounding ablation

Granulation tissue involving 10-25% of the area
surrounding ablation

Granulation tissue involving less than 10% of
the area surrounding ablation

Absence of granulation tissue

Granulation tissue

Ablation associated histology scaled scoring systems for evaluating healing responses

Collagen fibers appear densely compacted or
paucicellular and hyalinized (hypertrophic scarlike)

Collagen fibers are moderately courser and/or
compact (linearized)

Collagen fibers are slightly more courser and/or
compact (linearized)

Collagen has a slightly increased fiber density but
maintains a fibrillary (basket weave-like)
architecture

Absence of collagen fibrosis (collagen similar to
native tissue density)

Fibrosis
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0.5 ± 0.5
1.3 ± 0.4
0.0 ± 0.0
Early loose

Chronic inflammation score

Granulation tissue score

Fibrosis score

Overall healing stage

2.6 ± 0.88 mm
0.8 ± 1.3
2.0 ± 1.0
1.0 ± 0.7
1.8 ± 0.4
Primary healing

Ablation height

Acute inflammation score

Chronic inflammation score

Granulation tissue score

Fibrosis score

Overall healing stage

13.1 ± 4.48 mm
1.3 ± 0.32 mm
0.0 ± 0.0
2.3 ± 1.1
0.0 ± 0.0
3.0 ± 0.0
Secondary healed

Ablation width

Ablation height

Acute inflammation score

Chronic inflammation score

Granulation tissue score

Fibrosis score

Overall healing stage

Day 90 histology

13.9 ± 2.84 mm

Ablation width

Day 30 histology

0.8 ± 0.8

8.4 ± 1.56 mm

Ablation height

Acute inflammation score

16.3 ± 1.22 mm

Ablation width

Day 7 histology

Mean ± Std Dev
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3.0

0.0

2.0

0.0

1.3 mm

13.1

2.0

1.0

2.0

0.0

2.3 mm

14.0 mm

0.0

1.0

0.5

0.5

8.5 mm

16.3 mm

Median

3

0

1

0

0.9 mm

6.7 mm

1

0

1

0

1.9 mm

10.5 mm

0

1

0

0

6.5 mm

14.7 mm

Minimum

3

0

4

0

1.7 mm

19.3 mm

2

2

3

3

4.1 mm

17.3 mm

0

2

1

2

10.2 mm

17.8 mm

Maximum
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